19 completed, 18 recruiting, 11 terminated, 7 active not recruiting. 58 Phase 1, 35 Phase 2.
By phase and status
Follow BioNTech SE: new trials by email
Trials (filtered) newest first · largest first
All 58 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs BNT3219 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | 207 | 2026-11-01 | 2026-10-23 |
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn BNT3210 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | 173 | 2026-11-01 | 2026-10-21 |
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 55 | 2026-10-01 | 2026-11-10 |
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV BNT168, Placebo - HIV -1 Infection | Phase 1 | Recruiting | 126 | 2026-08-04 | 2026-10-14 |
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors BNT3214 - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Recruiting | 533 | 2026-03-30 | 2026-08-13 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Pumitamig, Ipilimumab, Cabozantinib - Advanced Renal Cell Carcinoma (RCC) | Phase 1 / Phase 2 | Recruiting | 474 | 2026-03-26 | 2026-10-23 |
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) Pumitamig, Ipilimumab - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | 198 | 2026-03-16 | 2026-10-23 |
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV BNT351, Placebo - HIV -1 Infection | Phase 1 | Recruiting | 67 | 2026-02-09 | 2026-09-01 |
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 BNT329, CA19-9-targeting monoclonal antibody - Advanced Solid Cancers | Phase 1 / Phase 2 | Recruiting | 245 | 2025-11-18 | 2026-10-15 |
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) BNT326, Pumitamig - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 880 | 2025-09-22 | 2026-11-13 |
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors BNT3212, Pumitamig - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 375 | 2025-08-27 | 2026-06-15 |
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors BNT326, Pumitamig, Itraconazole - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 1438 | 2025-08-12 | 2026-11-18 |
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer BNT314, Pumitamig, SoC chemotherapy treatment 1 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | 482 | 2025-07-18 | 2026-07-01 |
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer BNT324, BNT327 - Advanced Lung Cancer | Phase 1 / Phase 2 | Recruiting | 594 | 2025-05-02 | 2026-08-26 |
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer BNT323, BNT327 - Locally Advanced Breast Cancer, Unresectable Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | 380 | 2025-04-23 | 2026-11-10 |
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine - Influenza, COVID-19 (Coronavirus Disease 2019) | Phase 1 / Phase 2 | Completed | 2650 | 2025-02-10 | 2026-01-26 |
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors BNT317 DL1, BNT317 DL2, BNT317 DL3 - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 248 | 2025-01-13 | 2026-09-09 |
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose - COVID-19 | Phase 1 | Withdrawn | | 2025-01-06 | 2024-03-18 |
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine - Influenza,Human, COVID-19 | Phase 1 / Phase 2 | Completed | 1353 | 2024-11-11 | 2026-08-19 |
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis BNT331, Placebo - Bacterial Vaginosis | Phase 1 | Completed | 102 | 2024-07-01 | 2026-10-05 |
Showing 20 of 58. Sign in to see all of them.
Conditions studied
Carcinoma, Non-Small-Cell Lung (10) · COVID-19 (7) · Melanoma (5) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Neoplasm Metastasis (4) · Small Cell Lung Carcinoma (4) · Stomach Neoplasms (4) · Lethal Congenital Contracture Syndrome 2 (3) · Neoplasms (3) · Pancreatic Neoplasms (3) · Virus Diseases (3) · Bile Duct Neoplasms (2) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (2)
Interventions
pembrolizumab (6) · Carboplatin (5) · Itraconazole (3) · BNT162 Vaccine (2) · Cisplatin (2) · Etoposide (2) · Fluorouracil (2) · Gemcitabine (2) · Injections (2) · Ipilimumab (2) · Paclitaxel (2) · Ritonavir (2) · atezolizumab (2) · cemiplimab (2) · 130-nm albumin-bound paclitaxel (1)
Countries
United States (40) · Spain (20) · Germany (19) · United Kingdom (17) · Australia (14) · China (14) · France (7) · Italy (7) · Japan (6) · Taiwan (6) · Poland (5) · South Korea (5) · Turkey (Türkiye) (5) · Belgium (4) · Canada (4)
Top investigators
Lily Hu (2) · Christian Ottensmeier, Prof (1) · H. W. Nijman, MD/PhD (1) · Inhye Ahn, MD (1) · Ioannis Karydis, Dr (1) · Neeta Pandit-Taskar, MD (1) · Pierre-Yves Dietrich, Professor (1) · Wolfgang Wick, Professor (1)
Results publications
PMID 40245769, PMID 42286358, PMID 32728218, PMID 35688554, PMID 35771353, PMID 36125366, PMID 37079651, PMID 37164012, PMID 37592303, PMID 37860278, PMID 38366591, PMID 38776391, PMID 39197299, PMID 39762422, PMID 40347227, PMID 41530185, PMID 41708868, PMID 42235570, PMID 42325270
NIH funding
2023 (8), 2025 (4), 2017 (2), 2018 (2), 2019 (2), 2014 (1)